Clinical trial
A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily…
NCT02382939 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT02382939 |
|---|---|
| Title | A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency |
| Official title | A Multicentre, Multinational, Randomised, Open-labelled, Parallel-group, Active-controlled Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency |
| Acronym | REAL 2 |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Adult Growth Hormone Deficiency, Growth Hormone Disorder |
| Intervention type | Drug |
| Interventions | somapacitan, somatropin |
| Enrollment | 92 |
| Start date | Feb 12, 2015 |
| Primary completion | Jan 4, 2016 |
| Completion | Jan 4, 2016 |
| First posted | Mar 9, 2015 |
| Last update posted | Jul 9, 2020 |
| Countries | Denmark, France, Germany, Japan, Sweden, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: